Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor

Detalles Bibliográficos
Autores principales: Zhang, Huifang, Huang, Zineng, He, Liyu, Yuan, Fang, Sun, Lin, Liu, Fuyou, Xiao, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472505/
https://www.ncbi.nlm.nih.gov/pubmed/32814474
http://dx.doi.org/10.1080/0886022X.2020.1803087
_version_ 1783578998872211456
author Zhang, Huifang
Huang, Zineng
He, Liyu
Yuan, Fang
Sun, Lin
Liu, Fuyou
Xiao, Li
author_facet Zhang, Huifang
Huang, Zineng
He, Liyu
Yuan, Fang
Sun, Lin
Liu, Fuyou
Xiao, Li
author_sort Zhang, Huifang
collection PubMed
description
format Online
Article
Text
id pubmed-7472505
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74725052020-09-15 Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor Zhang, Huifang Huang, Zineng He, Liyu Yuan, Fang Sun, Lin Liu, Fuyou Xiao, Li Ren Fail Letter to the Editor Taylor & Francis 2020-08-19 /pmc/articles/PMC7472505/ /pubmed/32814474 http://dx.doi.org/10.1080/0886022X.2020.1803087 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Zhang, Huifang
Huang, Zineng
He, Liyu
Yuan, Fang
Sun, Lin
Liu, Fuyou
Xiao, Li
Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
title Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
title_full Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
title_fullStr Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
title_full_unstemmed Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
title_short Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
title_sort successful treatment of anti-epo antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472505/
https://www.ncbi.nlm.nih.gov/pubmed/32814474
http://dx.doi.org/10.1080/0886022X.2020.1803087
work_keys_str_mv AT zhanghuifang successfultreatmentofantiepoantibodyassociatedrefractoryanemiawithhypoxiainduciblefactorprolylhydroxylaseinhibitor
AT huangzineng successfultreatmentofantiepoantibodyassociatedrefractoryanemiawithhypoxiainduciblefactorprolylhydroxylaseinhibitor
AT heliyu successfultreatmentofantiepoantibodyassociatedrefractoryanemiawithhypoxiainduciblefactorprolylhydroxylaseinhibitor
AT yuanfang successfultreatmentofantiepoantibodyassociatedrefractoryanemiawithhypoxiainduciblefactorprolylhydroxylaseinhibitor
AT sunlin successfultreatmentofantiepoantibodyassociatedrefractoryanemiawithhypoxiainduciblefactorprolylhydroxylaseinhibitor
AT liufuyou successfultreatmentofantiepoantibodyassociatedrefractoryanemiawithhypoxiainduciblefactorprolylhydroxylaseinhibitor
AT xiaoli successfultreatmentofantiepoantibodyassociatedrefractoryanemiawithhypoxiainduciblefactorprolylhydroxylaseinhibitor

Ejemplares similares